German antibody‑drug conjugate (ADC) developer Tubulis closed a $361 million financing to accelerate clinical development of its lead ADC, TUB‑040, and expand testing into additional tumor types and earlier lines of therapy. The funding is one of the largest private raises in European oncology this year and supports upcoming clinical readouts. Tubulis plans to present first clinical data at a major oncology meeting and use proceeds to broaden its pipeline and scale manufacturing for cytotoxic payloads. Investors cited the company’s differentiated linker‑payload chemistry and modular ADC platform as drivers for the round. The cash infusion underscores investor appetite for next‑generation ADCs capable of broader activity and improved tolerability versus traditional chemotherapy.